Antidiabetic antihyperlipidemic and hepato-protective effect of Gluconorm-5: A polyherbal formulation in steptozotocin induced hyperglycemic rats

The antidiabetic, antihyperlipidemic, and hepato-protective effect of Gluconorm-5, was studied in steptozotocin (STZ) induced hyperglycemic rats. The hypoglycemic effect of single dose of Gluconorm-5 (150, 300 and 600 mg/kg body weight) made up of five plants namely Camellia sinensis, Punica granatum, Macrotyloma uniflorum, Foeniculum vulgare and Trigonella foenum-graecum was studied in normal, glucose loaded normal and diabetes-induced rats. The extent of antihyperlipidemic and liver-protective effect was studied by estimating the lipid profile, and the liver marker enzymes. Histopathological studies of the pancreatic tissue were also carried out with glibenclamide as standard antihyperglycemic agent. Fifteen days of oral feeding of the Gluconorm-5 (300 and 600 mg/kg) to diabetic rats resulted in a significant (P < 0.01) reduction of blood glucose, lipid profile, liver weight and marker enzymes as compared to those rats in whom STZ induced toxicity was untreated. The diabetic rats treated with the drug showed expanded islets as compared to the untreated diabetic rats, which showed the shrunken islets. The animals that received 300 mg/kg of Gluconorm-5 showed pronounced antidiabetic, antihyperlipidemic and hepato-protective effect in the present study, which was comparable with glibenclamide, a standard drug. Gluconorm-5 exerts potent antidiabetic antihyperlipidemic and hepato-protective effect, which can be used as adjuvant in the treatment of diabetes mellitus.